Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: Burden and potential for prevention
International Journal of Cancer, Volume 122, No. 8, Year 2008
Notification
URL copied to clipboard!
Description
Knowledge about the burden of Human Papillomavirus (HPV) infections in Sub-Saharan Africa is very limited. We collected cervical samples from 262 women from the general population and 241 tumor samples from women with invasive cervical cancer in Mozambique and tested them for HPV genotyping by the SPF 10-LiPA25 PCR system. Among the 195 women without cervical abnormalities by cytology HPV prevalence was 75.9%. In this group of women, the most frequently identified HPV types among HPV-positive women were in descending order of frequency: HPV51 (23.6%), HPV35 (19.6%), HPV18 (14.2%), HPV31 (13.5%) and HPV52 (12.8%). In women with cervical cancer HPV DNA detection was 100%. The type-specific distribution of the most frequent types in descending order of frequency was: HPV16 (47.0%), HPV18 (31.3%), HPV51 (14.8%), HPV52 (14.3%), HPV45 (12.6%), HPV35 (10.4%), HPV33 (4.8%) and HPV31 (2.6%). HPVs 16/18 and HPVs 16/18/31/45 were detected in 71.7% and 80.9% of cervical cancer tissue, respectively. While HPVs 51 and 35 were the two most common types in cytologically normal women in Mozambique, HPVs 16 and 18 remained the two most frequently identified types in cervical cancer. The introduction of an efficacious HPV 16/18 vaccine could potentially prevent the occurrence of 72% of cervical cancer cases and up to 81% of the cases if full cross-protection against HPVs 31 and 45 is assumed. © 2007 Wiley-Liss, Inc.
Authors & Co-Authors
Castellsagué, X.
Spain, Hospitalet de Llobregat
Institut D'investigació Biomedica de Bellvitge
Spain, Hospitalet de Llobregat
Institute Catala Oncologia
Klaustermeier, Jo Ellen
Spain, Hospitalet de Llobregat
Institut D'investigació Biomedica de Bellvitge
Carrilho, Carla
Mozambique, Maputo
Hospital Central de Maputo
Mozambique, Maputo
Universidade Eduardo Mondlane
Albero, Ginesa
Spain, Hospitalet de Llobregat
Institut D'investigació Biomedica de Bellvitge
Sacarlal, J.
Mozambique, Maputo
Universidade Eduardo Mondlane
Mozambique, Manhica
Centro de Investigação em Saúde de Manhiça Cism
Quint, Wim G.V.
Netherlands, Voorburg
Ddl Diagnostic Laboratory
Kleter, Bernhard
Netherlands, Voorburg
Ddl Diagnostic Laboratory
Lloveras, Belén
Spain, Hospitalet de Llobregat
Institut D'investigació Biomedica de Bellvitge
Ismail, Mamudo Rafik
Mozambique, Maputo
Hospital Central de Maputo
Mozambique, Maputo
Universidade Eduardo Mondlane
de Sanjosé, Sílvia
Spain, Hospitalet de Llobregat
Institut D'investigació Biomedica de Bellvitge
Bosch, Francisco Xavier
Spain, Hospitalet de Llobregat
Institut D'investigació Biomedica de Bellvitge
Alonso, Pedro Luís
Mozambique, Manhica
Centro de Investigação em Saúde de Manhiça Cism
Spain, Barcelona
Instituto de Salud Global de Barcelona
Menéndez, Clara
Mozambique, Manhica
Centro de Investigação em Saúde de Manhiça Cism
Spain, Barcelona
Instituto de Salud Global de Barcelona
Statistics
Citations: 60
Authors: 13
Affiliations: 7
Identifiers
Doi:
10.1002/ijc.23292
ISSN:
00207136
e-ISSN:
10970215
Research Areas
Cancer
Genetics And Genomics
Study Design
Cross Sectional Study
Study Locations
Mozambique
Participants Gender
Female